In this article, Richard Elliott provides an overview of recent developments under Canada’s Access to Medicines Regime (CAMR), and identifies key reforms needed to streamline the regime so that it can more easily be used to address public health problems in developing countries. Related Publications HIV/AIDS Policy & Law Review 13(1) July 2008
In England and Wales, where prosecutions for reckless HIV transmission have been taking place since 2003, the HIV sector persuaded the Crown Prosecution Service (CPS) to consult on the production of Legal Guidance for CPS prosecutors and caseworkers in this area of law, as well as an accompanying Policy Statement. In this article, Yusef Azad … Read more
The approach of Canada’s Government to Insite, North America’s first safer injecting facility, is one manifestation of what appears to be the government’s broader hostility to both evidence and human rights in public policy, at least insofar as that policy involves the health of people who use illicit drugs. A number of observations are warranted … Read more
By conservative estimates, hepatitis C (HCV) affects some 250,000–300,000 people in Canada. A chronic illness that causes liver failure, liver cancer and other serious health concerns, hepatitis C already weighs heavily on the health care system. Its public health and economic impact is expected to double in only a few years. Today, over 90 percent … Read more
The Government of Rwanda chooses to purchase a generic fixed-dose combination AIDS drug from Toronto-based generic pharmaceutical manufacturer Apotex, Inc., clearing the last major hurdle to the first use of “Canada’s Access to Medicines Regime”, and the first use anywhere of the August 30, 2003 decision of the General Council of the World Trade Organization … Read more